Statines en uw spieren*
Uit een Deense studie blijken weer eens de nadelen van statines, cholesterol verlagende medicijnen. 75% van de gebruikers van deze medicijnen blijkt spierpijnen ter ervaren doordat volgens deze studie de energieproductie in de spieren wordt verstoord. Verder blijken gebruikers van statines lage bloedwaarden
co-enzym Q10 te hebben en de daardoor gestoorde energieproductie zou wel eens de oorzaak van de spierpijnen kunnen zijn. Wel bijna 40% van de Deense vijfenzestigplussers gebruikt statines en dan te bedenken dat statines volgens eerdere studies
na vijf jaar lang gebruik slechts 0,5% minder kans geeft op doodgaan.
Cholesterol Medicine Affects Energy Production In Muscles
Up to 75 per cent of patients who take statins to treat elevated cholesterol levels may suffer from muscle pain. Scientists at the Center for Healthy Aging at the University of Copenhagen have now identified a possible mechanism underlying this unfortunate side effect. The results have just been published in the well-reputed Journal of American College of Cardiology.
Statin is a class of drugs which are used to treat high levels of blood cholesterol by way of inhibiting the liver's ability to produce cholesterol. Statins are the most potent drugs on the market for lowering low-density cholesterol (LDL). At present 600,000 Danes with elevated cholesterol levels take statins daily. 30-40 per cent of the older Danish population (ages 65+) are currently undergoing
treatment.
"A well-known side effect of statin therapy is muscle pain. Up to 75 per cent of the physically active patients undergoing treatment for high cholesterol experience pain. This may keep people away from either taking their medicine or from taking exercise - both of which are bad choices," says Professor Flemming Dela from the Center for Healthy Aging at the University of Copenhagen. He
continues:
"We have now shown that statin treatment affects the energy production in muscles. We are working on the assumption that this can be the direct cause of muscle weakness and pain in the patients."
Scientists also showed that the patients examined who were being treated with statins had low levels of the key protein Q10. Q10 depletion and ensuing lower energy production in the muscles could be the biological cause of the muscle pain that is a problem for many patients.
Side effects of statin therapy
About 40 per cent of the patients being treated with statins in Denmark are in so-called 'mono therapy' and thus are prescribed only this one drug. Presumably these are people who 'only' have high cholesterol and no other risk factors that could influence heart
health:
"The effect of statins is marginal for these patients - in a previous published Cochrane analysis only 0.5% reduction in all-cause mortality was detected, indicating that for every 200 patients taking statins daily for five years, one death would be prevented. This patient group is obviously interesting in light of the side effects of statin therapy," comments Professor Flemming
Dela.
The media influence patients
"The new study is the basis for a large planned research project, where we will focus broadly on patients undergoing statin treatment. We will look at statin consumption from a medical point of view, and will also investigate the media's influence on patients' acceptance or rejection of statins as a treatment option. Many contradictory views find their way into the public forum, and it can be difficult for patients to distinguish between fact and fiction," continues Professor Flemming Dela.
Scientists will also be looking at how home-monitoring of cholesterol levels influences patients - for example, does it make patients feel more or less secure when they take responsibility for their own health in this manner? The Center for Healthy Aging is currently seeking funding for the research project.
References:
Simvastatin Effects on Skeletal Muscle, Steen Larsen, MSci; Nis Stride, MD; Martin Hey-Mogensen, PhD; Christina N. Hansen, PhD; Lia E. Bang, MD; Henning Bundgaard, MD, DMSc; Lars B. Nielsen, MD, DMSc; Jørn W. Helge, PhD; Flemming Dela, MD, DMSc, Journal of American College of Cardiology. 2013;61(1):44-53. doi:10.1016/j.jacc.2012.09.036
University of Copenhagen (Januari 2013)
Reacties: